A
ARTBIO
A clinical-stage radiopharmaceutical biotechnology company focused on developing a new class of alpha radioligand therapies (ART)
About ARTBIO
ARTBIO is a pioneering startup in the field of cancer treatment, focusing on radioligand therapy (RLT). This innovative approach uses targeted radiation to kill cancer cells while sparing healthy tissues. The company operates in the biotechnology and healthcare market, primarily serving cancer patients and healthcare providers. ARTBIO’s business model revolves around developing and commercializing advanced cancer therapies.
The company has a differentiated pipeline with three main programs, including its lead program AB001, which has entered first-in-human studies. ARTBIO is also working on two additional targets, ABA and ABB, which remain undisclosed. The company’s therapies are designed with high affinity and selectivity to effectively target and kill tumors.
ARTBIO was founded in 2021, building on nearly a century of pioneering work in radiation therapy from the University of Oslo and Radium Hospital. The company collaborates with F Prime and Radforsk and is driven by a team of multidisciplinary experts with decades of experience in drug development. ARTBIO values inclusion, collaboration, and strong relationships with its team, partners, and healthcare providers.
The company makes money by developing its therapies through various stages of clinical trials and eventually bringing them to market. Once approved, these therapies can be sold to healthcare providers and institutions, generating revenue through sales and potential licensing agreements.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Cambridge, United States
- Employees
- 73
- Open positions
- 6
- Dealroom signal
- 82.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jul 2025 | $132M | $528M | Omega Funds · B Capital · Sofinnova Investments · Qatar Investment Authority | ↗ |
| SERIES AOther financing | Dec 2023 | $90M | $360M | Omega Funds · F-Prime · Third Rock Ventures | ↗ |
Growth signals
Latest recorded traffic for ARTBIO is 4.7K monthly website visits, up 56.7% over the last three months. ARTBIO's team grew 0% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
F-Prime
Omega Funds
Series A5 investors entered at this stage
Third Rock Ventures
B Capital
Sofinnova Investments
Qatar Investment Authority
Alexandria Venture Investments
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ARTBIO on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ARTBIO’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.